Palatine acquires TranScrip minority

The deal is the seventh investment from the firm's debut impact fund, which closed on £100m in September 2017. The fund targets businesses requiring equity tickets of less than £10m, with a focus on delivering positive social impact. It invests across themes including integrated health, ethical consumerism, lifestyle and wellbeing, and the circular economy.

The minority stake is described as "significant" in a statement.

As part of the investment, Palatine has appointed executive Paul McCluskey – the former CFO and CEO of Equistone Partners Europe-backed clinical research company Concept Life Sciences, and CFO of Synexus Clinical Research – as non-executive chairman.

Company
Headquartered in Thames valley, and founded in 2008, TranScrip provides a range of specialist professional services, including drug safety, pharmacovigilance, risk and portfolio management, commercial strategy, clinical development and operations, and virtual offerings.

People
Palatine Private Equity – Tristan Craddock (partner).
TranScrip – Flic Gabbay (managing partner).

Advisers
Equity – Gateley (legal); CIL (commercial due diligence); BDO (financial due diligence).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• UK / Ireland
• Support services
• Palatine Private Equity
• United Kingdom
• Minority investing